Search results for "Inde"

showing 10 items of 7365 documents

Apoptotic effect as biomarker of disease, severity and follow-up in interstitial cystitis

2018

Objective: To determine whether the apoptotic effect test could serve as a biomarker of severity in bladder pain syndrome/interstitial cystitis. Material and methods: A prospective study was conducted between January 2010 and January 2015, which included 57 patients diagnosed with interstitial cystitis and 49 diagnosed with chronic pelvic pain of gynaecological origin. The urine was exposed to cell cultures, and the urine's capacity for inducing apoptosis in the cultures was analysed. A statistical analysis was then conducted to assess whether the apoptotic effect was associated with the symptoms. Results: After performing an analysis of the association between the degree of apoptotic effec…

medicine.medical_specialtyCystitis Interstitial030232 urology & nephrologyApoptosisDiseaseUrineSeverity of Illness IndexGastroenterology03 medical and health sciences0302 clinical medicineInterstitial cystitisDisease severityInternal medicineDiagnosisHumansMedicineProspective StudiesProspective cohort studybusiness.industryPelvic painInterstitial cystitisBiomarkerGeneral Medicinemedicine.diseaseApoptosis030220 oncology & carcinogenesisBiomarker (medicine)Femalemedicine.symptombusinessFollow-Up StudiesActas Urológicas Españolas (English Edition)
researchProduct

Breath test using 13C methacetin does not seem to be useful in the assessment of liver function in girls with anorexia nervosa: a case control study

2018

Abstract Background Anorexia nervosa (AN) concerns approximately up to 1.8% of the pediatric female population. One of the complications that can occur in the course of this disease is acute liver failure. This study’s objective was to assess the usefulness of the 13C labeled Methacetin Breath Test (MBT) in the diagnostics of the liver function in girls with eating disorders. Methods For the study 81 girls aged 12 to 17 years were recruited, including 41 patients with confirmed diagnosis of AN (mean age 14.7 ± 1.48 years) and 40 age-matched controls. The diagnosis was based on the present Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria. Weight and height were measured…

medicine.medical_specialtyCytochrome P450AnorexiaLiver functionGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicinelcsh:RC799-869Breath testmedicine.diagnostic_testCumulative dosebusiness.industryGastroenterologyMethacetin breath testAnorexia nervosaGeneral MedicineHepatologymedicine.diseaseEating disordersAnorexia nervosa (differential diagnoses)030220 oncology & carcinogenesislcsh:Diseases of the digestive system. Gastroenterology030211 gastroenterology & hepatologyLiver functionmedicine.symptombusinessBody mass indexBMC Gastroenterology
researchProduct

The Use of a Nonimmersive Virtual Reality Programme in Anorexia Nervosa: A Single Case-Report

2011

Objective: People with anorexia nervosa (AN) experience high levels of fear and anxiety related to eating. The aim of this case report was to describe the use of a virtual reality (VR) programme developed to facilitate exposure to food as a supplement to treatment for a person with AN. Method: A 21-year-old patient with AN was given the VR module in addition to the Maudsley Model of Treatment for Adults with Anorexia Nervosa. Weight, eating disorder symptomatology (EDE-Q) and general psychopathology (DASS) were assessed before and after the module was delivered. Results: At the end of the module, the patient reported lower levels of anxiety, safety behaviours and fears related to food. Both…

medicine.medical_specialtyDASSdigestive oral and skin physiologymedicine.diseasePsychiatry and Mental healthClinical PsychologyDistressEating disordersAnorexia nervosa (differential diagnoses)Severity of illnessmedicineAnxietyYoung adultmedicine.symptomPsychologyPsychiatryBody mass indexClinical psychologyEuropean Eating Disorders Review
researchProduct

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre st…

2016

Ajuda rebuda: GlaxoSmithKline Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting. Design. Cross-sectional observational study. Setting. Spanish specialist outpatient clinics.Participants 403 adults with DM2 initiating GLP-1Ra treatment were included. Primary and secondary outcome measures Sociodemographic and DM2-related clinical data, including treatment …

medicine.medical_specialtyDM2Cross-sectional studymedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineInsulinaInternal medicinemedicineOutpatient clinic030212 general & internal medicineMedical prescriptionGlucagon-like peptide 1 receptorDiabetisbusiness.industryInsulinDiabetis mellitus tipus 2Type 2 Diabetes MellitusGeneral MedicineDiabetes mellitus tipo 2EndocrinologyConcomitantMalalties d'origen nutricionalbusinessBody mass index
researchProduct

The Value of BISAP Score for Predicting Mortality and Severity in Acute Pancreatitis: A Systematic Review and Meta-Analysis

2015

Purpose The Bedside Index for Severity in Acute Pancreatitis (BISAP) score has been developed to identify patients at high risk for mortality or severe disease early during the course of acute pancreatitis. We aimed to undertake a meta-analysis to quantify the accuracy of BISAP score for predicting mortality and severe acute pancreatitis (SAP). Materials and Methods We searched the databases of Pubmed, Embase, and the Cochrane Library to identify studies using the BISAP score to predict mortality or SAP. The pooled sensitivity, specificity, likelihood ratios, and diagnostic odds ratio (DOR) were calculated from each study and were compared with the traditional scoring systems. Results Twelv…

medicine.medical_specialtyDatabases Factuallcsh:MedicineSeverity of Illness Indexlaw.inventionlawSeverity of illnessOdds RatiomedicineHumanslcsh:ScienceIntensive care medicineMultidisciplinarybusiness.industryMortality ratelcsh:RCorrectionOdds ratiomedicine.diseaseSurvival AnalysisIntensive care unitSystematic reviewPancreatitisMeta-analysisAcute DiseasePancreatitisAcute pancreatitislcsh:QbusinessResearch ArticlePLOS ONE
researchProduct

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

The relationship between PASI and DLQI with itch, stress, and depression: Do we need additional decision‐making tools in psoriasis?

2019

medicine.medical_specialtyDepressionbusiness.industryMEDLINEDermatologyGeneral Medicinemedicine.diseaseSeverity of Illness IndexQuality of lifePsoriasisSeverity of illnessQuality of LifemedicineHumansPsoriasisPsychiatrybusinessDepression (differential diagnoses)Dermatologic Therapy
researchProduct

TNF-α blockade may lead to improvement of vascular function in psoriasis patients.

2021

Psoriasis is one of the most common chronic inflammatory skin diseases and at the same time a risk factor for cardiovascular disease. Interleukin-17A (IL-17A)-mediated inflammation in psoriasis may lead to vascular dysfunction. This study aimed at investigating whether anti-inflammatory treatment by tumor necrosis factor (TNF)-α blockade alters vascular function in psoriasis patients. A total of 11 patients with psoriasis who underwent treatment with either adalimumab (n = 8) or etanercept (n = 3), 10 healthy control individuals and 14 patients with coronary artery disease (CAD) were included in this study. Treatment response was assessed using the Psoriasis Area and Severity Index (PASI) s…

medicine.medical_specialtyDermatologyBiochemistryGastroenterologyEtanerceptCoronary artery diseasePsoriasis Area and Severity IndexInternal medicinePsoriasismedicineAdalimumabHumansPsoriasisRisk factorMolecular Biologybusiness.industryTumor Necrosis Factor-alphamedicine.diseaseBlockadeVasodilationVasoconstrictionChronic DiseaseTumor necrosis factor alphaTumor Necrosis Factor InhibitorsEndothelium Vascularbusinessmedicine.drugExperimental dermatologyREFERENCES
researchProduct

May Measurement Month 2019 : an analysis of blood pressure screening results from Poland

2021

Abstract May Measurement Month 2019 is the third edition of a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for blood pressure (BP) screening. We present data analysis from Poland. To evaluate the potential of opportunistic BP measurements as a tool for cardiovascular disease prevention programmes. To collect new country data for further annual comparisons. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in 201 sites in May 2019. BP was measured in 7072 subjects (mean age: 54 ± 15 years; 62.3% females). After multiple imputation, the age- and sex-standardized systolic BP (SBP) a…

medicine.medical_specialtyDiastole030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusEpidemiologyControlmedicineAcademicSubjects/MED00200030212 general & internal medicine1102 Cardiorespiratory Medicine and HaematologySecondary preventionbusiness.industryMean ageArticlesmedicine.diseaseTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningDisease awarenessDisease preventionCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct

May Measurement Month 2018 : an analysis of blood pressure screening campaign results from Poland

2020

Abstract Hypertension remains the most important cardiovascular risk factor in Poland. May Measurement Month is a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension and the need for blood pressure (BP) screening and demonstrating the potential of the opportunistic BP measurements. An opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in 146 sites in May 2018. Blood pressure was measured in 6450 subjects (mean age: 41 ± 15 years; 59% females). After multiple imputation, the age and sex standardized systolic and diastolic BP was 126.7/78.4 mmHg in the whole analysed group, 132.8/81.3 mmHg in subjects tak…

medicine.medical_specialtyDiastoleDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusControlmedicineAcademicSubjects/MED00200Risk factorSystole1102 Cardiorespiratory Medicine and Haematologybusiness.industry030229 sport sciencesArticlesmedicine.diseaseTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningDisease awarenessAlcohol intakeCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct